Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic

Leukemia

Volumn 18, Issue 5, 2004, Pages 895-908

  van der Burg, M ^a   Poulsen, T S ^b   Hunger, S P ^c   Beverloo, H B ^a   Smit, E M E ^a   Vang Nielsen, K ^b   Langerak, A W ^a   van Dongen, J J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AGILENT TECHNOLOGIES   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia (ALL); Chromosome aberrations; Fluorescence in situ hybridization (FISH); Fusion gene; Peptide nucleic acid (PNA); Split signal FISH

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DNA BINDING PROTEIN; GENE PRODUCT; HELIX LOOP HELIX PROTEIN; HOX PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN SIL; T CELL ACUTE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN; MLL PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAN PROTEIN; RANGTP BINDING PROTEIN 17; RANGTP-BINDING PROTEIN 17; REPRESSOR PROTEIN; TAL1 PROTEIN, HUMAN; TFPT PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETV6;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANALYTICAL ERROR; B CELL LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME 12P; CHROMOSOME 19P; CHROMOSOME 1Q; CHROMOSOME 22Q; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCATION; GENE PROBE; INTERMETHOD COMPARISON; KARYOTYPING; METAPHASE; PRIORITY JOURNAL; REVIEW; STEM CELL; T CELL LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; GENE TRANSLOCATION; GENETICS; HUMAN; METHODOLOGY; PROTO ONCOGENE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHROMOSOME ABERRATIONS; DNA-BINDING PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR; PROTO-ONCOGENE PROTEINS C-ETS; PROTO-ONCOGENES; RAN GTP-BINDING PROTEIN; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 2342629902     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403340     Document Type: Review

References (162)

1. Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol 1999; 36: 59-72.
2. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.
3. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-149.
4. Huret JL, Dessen P, Bernheim A. An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 2001; 15: 987-989.
5. Aplan PD, Raimondi SC, Kirsch IR. Disruption of the SCL gene by a t(1;3) translocation in a patient with T cell acute lymphoblastic leukemia. J Exp Med 1992; 176: 1303-1310.
6. Carroll AJ, Crist WM, Link MP, Amylon MD, Pullen DJ, Ragab AH, Buchanan GR, Wimmer RS, Vietti TJ. The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 76: 1220-1224.
7. Fitzgerald TJ, Neale GA, Raimondi SC, Goorha RM. c-tal, a helix-loop-helix protein, is juxtaposed to the T-cell receptor-beta chain gene by a reciprocal chromosomal translocation: t(1;7)(p321-q35). Blood 1991; 78: 2686-2695.
8. Francois S, Delabesse E, Baranger L, Dautel M, Foussard C, Boasson M et al. Deregulated expression of the TAL1 gene by t(1;5)(p32;q31) in patient with T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 1998; 23: 36-43.
9. Breit TM, Mol EJ, Wolvers-Tettero IL, Ludwig WD, van Wering ER, van Dongen JJ. Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med 1993; 177: 965-977.
10. Bernard OA, Busson-LeConiat M, Ballerini P, Mauchauffe M, Della Valle V, Monni R et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia 2001; 15: 1495-1504.
11. Helias C, Leymarie V, Entz-Werle N, Falkenrodt A, Eyer D, Costa JA et al. Translocation t(5;14)(q35;q32) in three cases of childhood T cell acute lymphoblastic leukemia: a new recurring and cryptic abnormality. Leukemia 2002; 16: 7-12.
12. Hayette S, Tigaud I, Maguer-Satta V, Bartholin L, Thomas X, Charrin C et al. Recurrent involvement of the MLL gene in adult T-lineage acute lymphoblastic leukemia. Blood 2002; 99: 4647-4649.
13. Moorman AV, Richards S, Harrison CJ. Involvement of the MLL gene in T-lineage acute lymphoblastic leukemia. Blood 2002; 100: 2273-2274.
14. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1990; 76: 117-122.
15. Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998; 16: 527-535.
16. Foa R, Vitale A, Mancini M. Cuneo A, Mecucci C. Elia L et al. E2APBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol 2003; 120: 484-487.
17. Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J et al. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study. Blood 1993; 81: 2110-2117.
18. Kikuchi A, Hayashi Y, Kobayashi S, Hanada R, Moriwaki K, Yamamoto K et al. Clinical significance of TAL1 gene alteration in childhood T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 1993; 7: 933-938.
19. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
20. Ballerini P, Blaise A, Busson-Le Coniat M, So XY; Zucman-Rossi J et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood 2002; 100: 991-997.
21. Harrison CJ. The management of patients with leukaemia: the role of cytogenetics in this molecular era. Br J Haematol 2000; 108: 19-30.
22. Lo Coco F, Mandelli F, Breccia M, Annino L, Guglielmi C, Petti MC et al. Southern blot analysis of ALL-1 rearrangements at chromosome 11q23 in acute leukemia. Cancer Res 1993; 53: 3800-3803.
23. Mathew S, Behm F, Dalton J, Raimondi S. Comparison of cytogenetics, Southern blotting, and fluorescence in situ hybridization as methods for detecting MLL gene rearrangements in children with acute leukemia and with 11q23 abnormalities. Leukemia 1999; 13: 1713-1720.
24. Rubnitz JE, Downing JR, Pui CH, Shurtleff SA, Raimondi SC, Evans WE et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997; 15: 1150-1157.
25. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118.
26. Breit TM, Beishuizen A, Ludwig WD, Mol EJ, Adriaansen HJ, van Wering ER et al. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 1993; 7: 2004-2011.
27. Wiemels JL, Leonard BC, Wang Y, Segal MR, Hunger SP, Smith MT et al. Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2002; 99: 15101-15106.
28. Wiemels JL, Alexander FE, Cazzaniga G, Biondi A, Mayer SP, Greaves M. Microclustering of TEL-AML1 translocation break-points in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2000; 29: 219-228.
29. van Dongen JJM, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT983936. Leukemia 2003; 17: 2257-2317.
30. van Dongen JJM, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio C et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
31. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409-417.
32. Gabert J, Beillard F, Van Der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 2003; 17: 2318-2357.
33. Kearney L. The impact of the new FISH technologies on the cytogenetics of haematological malignancies. Br J Haematol 1999; 104: 648-658.
34. van der Burg M, Smit B, Brinkhof B, Barendregt BH, Verschuren MCM, Dib M et al. A single split-signal FISH probe set allows detection of TAL1 translocations as well as SIL-TAL1 fusion genes in a single test. Leukemia 2002; 16: 755-761.
35. van der Burg M, Beverloo HB, Langerak AW, Wijsman J, van Drunen E, Slater R et al. Rapid and sensitive detection of all types of MLL gene translocations with a single FISH probe set. Leukemia 1999; 13: 2107-2113.
36. van Dongen JJM, Langerak AW. Molecular detection of chromosome aberrations (Split-signal FISH probe tehnology). International Patent 1998, PCT/NL98/00270.
37. Megonigal MD, Rappaport EF, Jones DH, Kim CS, Nowell PC, Lange Ell et al. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc Natl Acad Sci USA 1997; 94: 11583-11588.
38. Felix CA, Jones DH. Panhandle PCR: a technical advance to amplify MLL genomic translocation breakpoints. Leukemia 1998; 12: 976-981.
39. Britten RJ, Kohne DE. Repeated sequences in DNA. Hundreds of thousands of copies of DNA sequences have been incorporated into the genomes of higher organisms. Science 1968; 161: 529-540.
40. Brosius L. Retroposons-seeds of evolution. Science 1991; 251: 753.
41. Novick GE, Batzer MA, Deiniger PL, Herrera RJ. The mobile genetic element Alu in the human genome. Bioscience 1996; 46: 32-41.
42. Singer MF. SINEs and LINEs: highly repeated short and long interspersed sequences in mammalian genomes. Cell 1982; 28: 433-434.
43. Korenberg JR, Rykowski MC. Human genome organization: Alu, lines, and the molecular structure of metaphase chromosome bands. Cell 1988; 53: 391-400.
44. Landegent JE, Jansen in de Wal N, Dirks RW, Baao F, van der Ploeg M. Use of whole cosmid cloned genomic sequences for chromosomal localization by non-radioactive in situ hybridization. Hum Genet 1987; 77: 366-370.
45. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254: 1497-1500.
46. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993; 365: 566-568.
47. Nielsen KV, Müller S, Poulsen TS, Gabs S, Schonau A. Combined use of PHA and DNA for fluorescence in situ hybridization (FISH). In: Nielsen PE (ed). Peptide Nuclei Acid, Protocols and Applications, 2nd edn. Wymondham: Horizon Scientific Press, 2003, pp 227-260.
48. van Dongen JJM, Vang Nielsen K, Pluzek KJ, Adelhorst K. Method and probes for the detection of chromosome aberrations (FISH probe/PNA based technology). International Patent 1999, PCT/DK99/00245.
49. Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989; 56: 777-783.
50. Shikano T, Kaneko Y, Takazawa M, Ueno N, Ohkawa M, Fujimoto T. Balanced and unbalanced 1;19 translocation-associated acute lymphoblastic leukemias. Cancer 1986; 58: 2239-2243.
51. Pui CH, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J Clin Oncol 1994; 12: 2601-2606.
52. Secker-Walker LM, Berger R, Fenaux P, Lai JL, Nelken B, Garson M et al. Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. Leukemia 1992; 6: 363-369.
53. Mellentin JD, Murre C, Donlon TA, McCaw PS, Smith SD, Carroll AJ et al. The gene for enhancer binding proteins E12/E47 lies at the t(1;19) breakpoint in acute leukemias. Science 1989; 246: 379-382.
54. Mellentin JD, Nourse J, Hunger SP, Smith SD, Cleary ML. Molecular analysis of the t(1;19) breakpoint cluster region in pre-B cell acute lymphoblastic leukemias. Genes Chromosomes Cancer 1990; 2: 239-247.
55. Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD et al. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 1990; 60: 535-545.
56. Boomer T, Varella-Garcia M, McGavran L, Meltesen L, Olsen AS, Hunger SP. Detection of E2A translocations in leukemias via fluorescence in situ hybridization. Leukemia 2001; 15: 95-102.
57. Aspland SE, Bendall HH, Murre C. The role of E2A-PBX1 in leukemogenesis. Oncogene 2001; 20: 5708-5717.
58. Herblot S, Aplan PD, Hoang T. Gradient of E2A activity in B-cell development. Mol Cell Biol 2002; 22: 886-900.
59. Hunger SP, Ohyashiki K, Toyama K, Cleary ML. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev 1992; 6: 1608-1620.
60. Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992; 257: 531-534.
61. Seidel MG, Look AT. E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene 2001; 20: 5718-5725.
62. Brambillasca F, Mosna G, Colombo M, Rivolta A, Caslini C, Minuzzo M et al. Identification of a novel molecular partner of the E2A gene in childhood leukemia. Leukemia 1999; 13: 369-375.
63. Kamps MP, Murre C, Sun XH, Baltimore D. A new homeohox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 1990; 60: 547-555.
64. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762-769.
65. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa III R, Patel Y, Harden A et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 1991; 88: 10735-10739.
66. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
67. Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17: 700-706.
68. Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II. Blood 1993; 82: 3705-3711.
69. Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol 2001; 114: 539-543.
70. Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Mugneret F et al. Ten novel 11q23 chromosomal partner sites. Leukemia 1998; 12: 811-822.
71. Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S et al. Hematologic malignancies with t(4;11)(q21;q23) - a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia 1998; 12: 779-787.
72. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992; 71: 701-708.
73. Moorman AV, Hagemeijer A, Charrin C, Rieder H, Secker Walker LM. The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. European 11q23 Workshop participants. Leukemia 1998; 12: 805-810.
74. Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM. Hematological malignancies with t(9;11)(p21-22;q23) - a laboratory and clinical study of 125 cases. European 11q23 Workshop participants. Leukemia 1998; 12: 792-800.
75. Lillington DM, Young BD, Berger R, Martineau M, Moorman AV, Secker-Walker LM. The t(10;11)(p12;q23) translocation in acute leukaemia: a cytogenetic and clinical study of 20 patients. European 11q23 Workshop participants. Leukemia 1998; 12: 801-804.
76. Martineau M, Berger R, Lillington DM, Moorman AV, Secker-Walker LM. The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. EU Concerted Action 11q23 Workshop participants. Leukemia 1998; 12: 788-791.
77. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71: 691-700.
78. Zeleznik-Le NJ, Harden AM, Rowley JD. 11q23 translocations split the 'AT-hook' cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci USA 1994; 91: 10610-10614.
79. Fidanza V, Melotti P, Yano T, Nakamura T, Bradley A, Canaani E et al. Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro. Cancer Res 1996; 56: 1179-1183.
80. Kobayashi H, Espinosa R, Thirman MJ, Gill HJ, Fernaold AA, Diaz MO et al. Heterogeneity of breakpoints of 11q23 rearrangements in hematologic malignancies identified with fluorescence in situ hybridisation. Blood 1993; 82: 547-551.
81. Johansson B, Moorman AV, Secker-Walker LM. Derivative chromosomes of 11q23 translocations in hematologic malignancies. Leukemia 1998; 12: 828-833.
82. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20: 5695-5707.
83. Nilson I, Lochner K, Siegler G, Greil J, Beck JD, Fey GH et al. Exon/intron structure of the human ALL-1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukaemias. Br J Haematol 1996; 93: 966-972.
84. von Bergh A, Emanuel B, van Zelderen-Bhola S, Smetsers T, van Soest R, Stul M et al. A DNA probe combination for improved detection of MLL/11q23 breakpoints by double-color interphase-FISH in acute leukemias. Genes Chromosomes Cancer 2000; 28: 14-22.
85. Beverloo HB, Le Coniat M, Wijsman J, Lillington DM, Bernard O, de Klein A et al. Breakpoint heterogeneity in t(10;11) translocation in AML-M4/M5 resulting in fusion of AF10 and MLL is resolved by fluorescent in situ hybridization analysis. Cancer Res 1995; 55: 4220-4224.
86. Golub TR, McLean T, Stegmaier K, Carroll M, Tomasson M, Gilliland DG. The TEL gene and human leukemia. Biochim Biophys Acta 1996; 1288: M7-M10.
87. Rubnitz JE, Pui CH, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999; 13: 6-13.
88. Baens M, Peeters P, Guo C, Aerssens J, Marynen P. Genomic organization of TEL: the human ETS-variant gene 6. Genome Res 1996; 6: 404-413.
89. Wlodarska I, La Starza R, Baens M, Dierlamm J, Uyttebroeck A, Selleslag D et al. Fluorescence in situ hybridization characterization of new translocations involving TEL (ETV6) in a wide spectrum of hematologic malignancies. Blood 1998; 91: 1399-1406.
90. Seeger K, von Stackelberg A, Taube T, Buchwald D, Korner G, Suttorp M et al. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol 2001; 19: 3188-3193.
91. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-1989.
92. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffe M, Jonveaux P et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86: 4263-4269.
93. Raynaud SD, Dastugue N, Zoccola D, Shurtleff SA, Mathew S, Raimondi SC. Cytogenetic abnormalities associated with the t(12;21): a collaborative study of 169 children with t(12;21)-positive acute lymphoblastic leukemia. Leukemia 1999; 13: 1325-1330.
94. Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996; 87: 2891-2899.
95. Cave H, Cacheux V, Raynaud S, Brunie G, Bakkus M, Cochaux P et al. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. Leukemia 1997; 11: 1459-1564.
96. Patel N, Goff LK, Clark T, Ford AM, Foot N, Lillington D et al. Expression profile of wild-type ETV6 in childhood acute leukaemia. Br J Haematol 2003; 122: 94-98.
97. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.
98. Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002; 95: 1673-1684.
99. Wong S, Witte ON. Modeling Philadelphia chromosome positive leukemias. Oncogene 2001; 20: 5644-5659.
100. Arico M, Valsecchi MC, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
101. Diekmann D, Brill S, Garrett MD, Totty N, Hsuan J, Monfries C et al. Bcr encodes a GTPase-activating protein for p21rac. Nature 1991; 351: 400-402.
102. Chissoe SL, Bodenteich A, Wang YF, Wang YP, Burian D, Clifton SW et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 1995; 27: 67-82.
103. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
104. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554.
105. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988; 239: 775-777.
106. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987; 235: 85-88.
107. Selleri L, von Lindern M, Hermans A, Meijer D, Torelli G, Grosveld G. Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript. Blood 1990; 75: 1146-1153.
108. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8: 208-211.
109. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88: 2410-2414.
110. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738-743.
111. de la Fuente J, Merx K, Steer EJ, Muller M, Szydlo RM, Maywald O, Berger U, Hehlmann R, Goldman JM, Cross NC, Melo JV, Hochlaus A. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 2001; 98: 2879-2880.
112. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205-2212.
113. Delabesse E, Bernard M, Meyer V, Smit L, Pulford K, Cayuela JM et al. TAL1 expression does not occur in the majority of T-ALL blasts. Br J Haematol 1998; 102: 449-457.
114. Bash RO, Hall S, Timmons CF, Crist WM, Amylon M, Smith RG et al. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study. Blood 1995; 86: 666-676.
115. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 1995; 373: 432-434.
116. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 1996; 86: 47-57.
117. Robb L, Elwood NJ, Elefanty AG, Kontgen F, Li R, Barnett LD et al. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J 1996; 15: 4123-4129.
118. Baer R. TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin Cancer Biol 1993; 4: 341-347.
119. Aplan PD, Lombardi DP, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR. Disruption of the human SCL locus by 'illegitimate' V-(D)-J recombinase activity. Science 1990; 250: 1426-1429.
120. Bernard O, Lecointe N, Jonveaux P, Souyri M, Mauchauffe M, Berger R et al. Two site-specific deletions and t(1;14) translocation restricted to human T-cell acute leukemias disrupt the 5′ part of the tal-1 gene. Oncogene 1991; 6: 1477-1488.
121. Delabesse F, Bernard M, Landman-Parker J, Davi F, Leboeuf D, Varet B et al. Simultaneous SIL-TAL1 RT-PCR detection of all tal(D) deletions and identification of novel tal(d) variants. Br J Haematol 1997; 99: 901-907.
122. Szczepanski T, Langerak AW, Wolvers-Tettero IL, Ossenkoppele GJ, Verhoef G, Stul M et al. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease. Leukemia 1998; 12: 1081-1088.
123. Aplan PD, Lombardi DP, Kirsch IR. Structural characterization of SIL, a gene frequently disrupted in T-cell acute lymphoblastic leukemia. Mol Cell Biol 1991; 11: 5462-5469.
124. Aplan PD, Lombardi DP, Reaman GH, Sather HN, Hammond GD, Kirsch IR. Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood 1992; 79: 1327-1333.
125. Brown L, Cheng JT, Chen Q, Siciliano MJ, Crist W, Buchanan G et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J 1990; 9: 3343-3351.
126. Bernard O, Guglielmi P, Jonveaux P, Cherif D, Gisselbrecht S, Mauchauffe M et al. Two distinct mechanisms for the SCL gene activation in the t(1;14) translocation of T-cell leukemias. Genes Chromosomes Cancer 1990; 1: 194-208.
127. Aplan PD, Johnson BE, Russell E, Chervinsky DS, Kirsch IR. Cloning and characterization of TCTA, a gene located at the site of a t(1;3) translocation. Cancer Res 1995; 55: 1917-1921.
128. Cave H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 2003; 22: 22.
129. Gottgens B, Gilbert JG, Barton LM, Grafham D, Rogers J, Bentley DR et al. Long-range comparison of human and mouse SCL loci: localized regions of sensitivity to restriction endonucleases correspond precisely with peaks of conserved noncoding sequences. Genome Res 2001; 11: 87-97.
130. Mauvieux L, Leymarie V, Helias C, Perrusson N, Falkenrodt A, Lioure B et al. High incidence of Hox11L2 expression in children with T-ALL. Leukemia 2002; 16: 2417-2422.
131. Dear TN, Sanchez-Garcia I, Rabbitts TH. The HOX11 gene encodes a DNA-binding nuclear transcription factor belonging to a distinct family of homeobox genes. Proc Natl Acad Sci USA 1993; 90: 4431-4435.
132. Hansen-Hagge TE, Schafer M, Kiyoi H, Morris SW, Whitlock JA, Koch P et al. Disruption of the RanBP17/Hox11L2 region by recombination with the TCRdelta locus in acute lymphoblastic leukemias with t(5;14)(q34;q11). Leukemia 2002; 16: 2205-2212.
133. Koch P, Bohlmann I, Schafer M, Hansen-Hagge TE, Kiyoi H, Wilda M et al. Identification of a novel putative Ran-binding protein and its close homologue. Biochem Biophys Res Commun 2000; 278: 241-249.
134. Cinti R, Fava M, Sancandi M, Matera I, Ravazzolo R, Ceccherini I. Assignment of the HOX11L2 gene to human chromosome band 5q35.1 and of its murine homolog to mouse chromosome hands 11A4-A5 by in situ hybridization. Cytogenet Cell Genet 2001; 92: 354-355.
135. de Boer CJ, Vaandrager JW, van Krieken JH, Holmes Z, Kluin PM, Schuuring E. Visualization of mono-allelic chromosomal aberrations 3′ and 5′ of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization. Oncogene 1997; 15: 1599-1603.
136. Vaandrager JW, Schuuring E, Philippo K, Kluin PM. V(D)J recombinase-mediated transposition of the BCL2 gene to the IGH locus in follicular lymphoma. Blood 2000; 96: 1947-1952.
137. Poulsen TS, Silahtaroglu AN, Gisselo CG, Gaarsdal E, Rasmussen T, Tommerup N et al. Detection of illegitimate rearrangement within the immunoglobulin locus on 14q32.3 in B-cell malignancies using end-sequenced probes. Genes Chromosomes Cancer 2001; 32: 265-274.
138. Poulsen TS, Silahtaroglu AN, Gisselo CG, Tommerup N, Johnsen HE, Gaarsdal E et al. Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes Detection of illegitimate rearrangement within the immunoglobulin locus on 14q32.3 in B-cell malignancies using end-sequenced probes. Leukemia 2002; 16: 2148-2155.
139. Gesk S, Martin-Subero JI, Harder L, Luhmann B, Schlegelberger B, Calasanz MJ et al. Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci. Leukemia 2003; 17: 738-745.
140. Jansen MJWC, Van der Velden VHJ, Den Boer ML, Pieters R, Van Dongen JJM. Immunobiological diversity in infant acute lymphoblastic leukemia. Blood 2003; 102: 21a.
141. Dimartino JF, Cleary ML. MII rearrangements in haematological malignancies: lessons from clinical and biological studies. Br J Haematol 1999; 106: 614-626.
142. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003; 102: 2395-2402.
143. Huret JL. 11q23 rearrangements in leukaemia. Atlas Genet Cytogenet Oncol Haematol 2003. http://www.infobiogen.fr/services/chromcancer/Anomalies/11q23ID1030.html.
144. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917-4921.
145. Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995; 85: 3662-3670.
146. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
147. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM et al. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995; 55: 34-38.
148. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90: 2535-2540.
149. Buijs A, Sherr S, van Baal S, van Bezouw S, van der Plas D, Geurts van Kessel A et al. Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Oncogene 1995; 10: 1511-1519.
150. Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CD, Dainton M et al. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood 1996; 88: 682-689.
151. Voutsadakis IA, Maillard N. Acute myelogenous leukemia with the t(3;12)(q26;p13) translocation: case report and review of the
152. Cools J, Bilhou-Nabera C, Wlodarska I, Cabrol C, Talmant P, Bernard P et al. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12)(q11-q12;p13). Blood 1999; 94: 1820-1824.
153. Cazzaniga G, Tosi S, Aloisi A, Giudici G, Daniotti M, Pioltelli P et al. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood 1999; 94: 4370-4373.
154. Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999; 93: 1355-1363.
155. Chase A, Reiter A, Burci L, Cazzaniga G, Biondi A, Pickard J et al. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). Blood 1999; 93: 1025-1031.
156. Qiao Y, Ogawa S, Hangaishi A, Yuji K, Izutsu K, Kunisato A et al. Identification of a novel fusion gene, TTL, fused to ETV6 in acute lymphoblastic leukemia with t(12;13)(p13;q14), and its implication in leukemogenesis. Leukemia 2003; 17: 1112-1120.
157. Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towatari M et al. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 2001; 97: 1050-1055.
158. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 2001; 61: 4666-4670.
159. Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA et al. PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13). Leukemia 2003; 17: 1121-1123.
160. Penas EM, Cools J, Algenstaedt P, Hinz K, Seeger D, Schafhausen P et al. A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene. Genes Chromosomes Cancer 2003; 37: 79-83.
161. Salomon-Nguyen F, Della-Valle V, Mauchauffe M, Busson-Le Coniat M, Ghysdael J, Berger R et al. The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. Proc Natl Acad Sci USA 2000; 97: 6757-6762.
162. van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996; 87: 5213-5217.